Zotarolimus-eluting stent utilization in small-vessel coronary artery disease (ZEUS)

• Published in: Heart and vessels Vol. 29; no. 1; pp. 29 - 34
• Main Authors: Jim, Man-Hong, Yiu, Kai-Hang, Fung, Raymond Chi-yan, Ho, Hee-Hwa, Ng, Andrew Kei-Yan, Siu, Chung-Wah, Chow, Wing-Hing
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01.01.2014; Springer Nature B.V
• Subjects: Aged; Biomedical Engineering and Bioengineering; Cardiac Surgery; Cardiology; Cardiovascular Agents - administration & dosage; Cardiovascular disease; Clinical outcomes; Coronary Angiography; Coronary Restenosis - etiology; Coronary Stenosis - diagnostic imaging; Coronary Stenosis - therapy; Coronary vessels; Drug therapy; Drug-Eluting Stents; Female; Humans; Male; Medicine; Medicine & Public Health; Middle Aged; Myocardial Infarction - etiology; Original Article; Percutaneous Coronary Intervention - adverse effects; Percutaneous Coronary Intervention - instrumentation; Prosthesis Design; Retrospective Studies; Sirolimus - administration & dosage; Sirolimus - analogs & derivatives; Stents; Time Factors; Treatment Outcome; Vascular Surgery; Angiographic restenosis; Zotarolimus-eluting stent; Small-vessel disease
• ISSN: 0910-8327; 1615-2573
• DOI: 10.1007/s00380-013-0327-0

The role of the second-generation zotarolimus-eluting stent RESOLUTE in small-vessel coronary artery disease is unclear. The aim of this study was examine the angiographic results of RESOLUTE in de novo coronary lesions of ≥50 % diameter stenosis in target vessels ≤2.5 mm. From August 2008 to April 2010, 142 symptomatic patients with 159 lesions who fitted the inclusion criteria were treated with RESOLUTE. The mean age of patients was 66 ± 10 years, with male predominance (66 %). Diabetes mellitus was found in 62 (43.7 %) patients, whereas multivessel disease was observed in 105 (73.9 %). The mean stent size and length used were 2.33 ± 0.13 and 22 ± 8 mm, respectively. Follow-up angiography was performed on 143 (89.9 %) lesions in 127 (89.4 %) patients at a mean of 10.3 ± 3.6 months. Angiographic restenosis was found in 9 (6.3 %) lesions; the late loss was 0.26 ± 0.34 mm. At 1-year follow-up there were four cardiovascular deaths, two nonfatal myocardial infarctions, and six repeated revascularizations. The resultant major adverse cardiac event rate was 8.5 %. The use of RESOLUTE to treat small-vessel disease is associated with good clinical and angiographic outcomes at 1 year.